Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates
作者: Alfonso IorioKathelijn FischerVictor BlanchetteSavita RangarajanGuy YoungMassimo Morfini
作者单位: 1Alfonso Iorio, McMaster University, 1280 Main St West, Hamilton, ON L8S 4K1, Canada, Tel.: +1 905 525 9140 ext 22421, Fax: +1 905 526 8447, E-mail: iorioa@mcmaster.ca
刊名: Thromb Haemost, 2017, Vol.117 (6), pp.1023-1030
来源数据库: Schattauer GmbH
DOI: 10.1160/TH16-12-0942
关键词: Haemophilia Bfactor IXpharmacokineticsextended half-lifetailoredpersonalised
原始语种摘要: The prophylactic administration of factor IX (FIX) is considered the most effective treatment for haemophilia B. The inter-individual variability and complexity of the pharmacokinetics (PK) of FIX, and the rarity of the disease have hampered identification of an optimal treatment regimens. The recent introduction of extended half-life recombinant FIX molecules (EHL-rFIX), has prompted a thorough reassessment of the clinical efficacy, PK and pharmacodynamics of plasma-derived and recombinant FIX. First, using longer sampling times and multi-compartmental PK models has led to more precise (and favourable) PK for FIX than was appreciated in the past. Second, investigating the distribution of FIX in the body beyond the vascular space (which is implied by its complex kinetics) has opened a new...
全文获取路径: Schattauer 出版社  (合作)
影响因子:6.094 (2012)

  • accounting 会计
  • FIX 固定设备
  • haemophilia 血友病
  • standard 标准
  • treatment 处理
  • expertise 专家评价
  • reassessment 再确定
  • optimal 最佳的
  • costs 费用
  • extended 扩展